NASDAQ:FLXN
Delisted
Flexion Therapeutics Stock News
$9.12
+0 (+0%)
At Close: May 27, 2022
Northland Securities Keeps a Hold Rating on Esperion (ESPR)
11:06am, Thursday, 16'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR) today and set a price target of $42.00. The company's shares closed
Northland Securities Keeps a Hold Rating on Esperion (ESPR)
11:06am, Thursday, 16'th Apr 2020
Northland Securities analyst
Carl Byrnes
maintained a
Hold
rating on Esperion (
ESPR
–
Research Report
) today and set a price target of
$42.00
. The company’s shares closed last Wednesday at $34.
Flexion Therapeutics (FLXN) Receives a Buy from Needham
10:29am, Wednesday, 15'th Apr 2020
Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $36.00. The company's shares closed
Analysts Offer Insights on Healthcare Companies: PolarityTE (PTE) and Atricure (ATRC)
01:46pm, Monday, 13'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE) and Atricure (ATRC) with bullish
Analysts Offer Insights on Healthcare Companies: PolarityTE (NASDAQ: PTE) and Atricure (NASDAQ: ATRC)
01:46pm, Monday, 13'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (
PTE
–
Research Report
) and Atricure (
ATRC
–
Research Report
) with bullish sentiment
Goldman Sachs Group Inc. Has $3.37 Million Stock Position in Flexion Therapeutics Inc (NASDAQ:FLXN)
08:28am, Sunday, 12'th Apr 2020
Goldman Sachs Group Inc. increased its position in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 25.5% during the fourth quarter, according to the company in its most recent 13F filing with the
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
10:59am, Thursday, 09'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Buy rating on Aridis Pharmaceuticals (ARDS) today and set a price target of $22.00. The company's
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
10:59am, Thursday, 09'th Apr 2020
Northland Securities analyst
Carl Byrnes
maintained a
Buy
rating on Aridis Pharmaceuticals (
ARDS
–
Research Report
) today and set a price target of
$22.00
. The company’s shares closed last Wedn
Northland Securities Thinks PolarityTE's Stock is Going to Recover
12:59pm, Wednesday, 08'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Buy rating on PolarityTE (PTE) today and set a price target of $8.00. The company's shares closed
Northland Securities Thinks PolarityTE’s Stock is Going to Recover
12:59pm, Wednesday, 08'th Apr 2020
Northland Securities analyst
Carl Byrnes
maintained a
Buy
rating on PolarityTE (
PTE
–
Research Report
) today and set a price target of
$8.00
. The company’s shares closed last Tuesday at $0.87,
Analysts Offer Insights on Healthcare Companies: Cutera (CUTR) and GW Pharma (GWPH)
11:33am, Wednesday, 08'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cutera (CUTR) and GW Pharma (GWPH). Cutera (CUTR) In a report released
Analysts Offer Insights on Healthcare Companies: Cutera (NASDAQ: CUTR) and GW Pharma (NASDAQ: GWPH)
11:33am, Wednesday, 08'th Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cutera (CUTR – Research Report)
Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
08:30pm, Tuesday, 07'th Apr 2020
BURLINGTON, Mass., April 07, 2020 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will.
Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
08:30pm, Tuesday, 07'th Apr 2020
BURLINGTON, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and...
ASX soars: Aus shares close 4.3% higher
11:31pm, Monday, 06'th Apr 2020
06 Apr 2020 - The Australian share market had a positive day of trade to finish 4.3 per cent up. Paradigm Biopharmaceuticals (ASX:PAR) to raise $35 million.
